UNIGE document Scientific Article
previous document  unige:99092  next document
add to browser collection
Title

Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia
Authors
Maury, Sébastien
Chevret, Sylvie
Thomas, Xavier
Heim, Dominik
Leguay, Thibaut
Huguet, Françoise
Chevallier, Patrice
Hunault, Mathilde
show hidden authors show all authors [1 - 22]
Published in New England Journal of Medicine. 2016, vol. 375, no. 11, p. 1044-1053
Abstract Treatment with rituximab has improved the outcome for patients with non-Hodgkin's lymphoma. Patients with B-lineage acute lymphoblastic leukemia (ALL) may also have the CD20 antigen, which is targeted by rituximab. Although single-group studies suggest that adding rituximab to chemotherapy could improve the outcome in such patients, this hypothesis has not been tested in a randomized trial.
Keywords Adolescent — Adult — Antigens, CD20/analysis — Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use — Disease-Free Survival — Female — Follow-Up Studies — Humans — Male — Middle Aged — Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy/immunology — Prognosis — Remission Induction — Rituximab/administration & dosage/adverse effects — Young Adult
Identifiers
PMID: 27626518
Full text
Article (Published version) (294 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Faculté de médecine / Section de médecine clinique / Département de médecine
Research group Leucémie et transplantation allogénique de cellules souches hématopoïétiques (982)
Citation
(ISO format) 		MAURY, Sébastien et al. Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. In: New England Journal of Medicine, 2016, vol. 375, n° 11, p. 1044-1053. https://archive-ouverte.unige.ch/unige:99092

140 hits

0 download

Contact an author

Update request

Update

Deposited on : 2017-11-16

Export document
Format :
Citation style :